ERBB2 and breast cancer: Triple-negative breast cancer (TNBC) is a particularly aggressive molecular BC subtype characterized by the lack of expression of estrogen and progesterone receptors and HER2 oncoprotein, the three “gold standard” actionable biotargets for luminal and HER2-enriched BCs [2].